

Elafibranor, PPARalpha/delta agonist

Catalog	Unit
TBI3901-5MG	5 mg
TBI3901-25MG	25 mg

Product Details

Formal Name: 2-[2,6-Dimethyl-4-[(E)-3-(4-methylsulfonylphenyl)-3-oxoprop-1-enyl]phenoxy]-2-methylpropanoic acid

Alternate Names: GFT505

Molecular Formula: C₂₂H₂₄O₄S

Formula Weight: 384.50

CAS Number: 923978-27-2


Purity: >98%

Formulation: powder

Solubility: Soluble in DMSO (up to at least 25 mg/ml)

Storage: -20°C

Stability: ≥ 1 year.



Applications

PPARalpha/delta agonist

Functions

Elafibranor is a dual PPARalpha/delta agonist (EC₅₀ PPARalpha = 10-20 nM; PPARdelta = 100-150 nM). It was able to decrease plasma triglycerides levels, increase HDL cholesterol levels in human studies, and improve hepatic and peripheral insulin sensitivity. Elafibranor's antidiabetic effects in db/db were without the adverse cardiac effects seen in PPARgamma agonism. Elafibranor has also been shown to have therapeutic promise in the treatment of nonalcoholic steatohepatitis (NASH).

Application Procedures

First dissolved in DMSO (up to at least 25 mg/ml), then diluted to aqueous buffer. Solutions in DMSO may be stored at -20° for up to 1 month.

For research use only.